Skip to content
The Policy VaultThe Policy Vault

Zelboraf (vemurafenib) — Medica

Melanoma (unresectable, advanced, or metastatic)

Initial criteria

  • age ≥ 18 years
  • unresectable, advanced, or metastatic melanoma
  • BRAF V600 mutation-positive disease

Approval duration

1 year